TY - EJOU
AU - Hu, Chunya
AU - He, Yu
TI - Formononetin Inhibits Non-Small Cell Lung Cancer Proliferation via Regulation of mir-27a-3p through p53 Pathway
T2 - Oncologie
PY - 2021
VL - 23
IS - 2
SN - 1765-2839
AB - Objective: The aim of the present study was to investigate the anti-tumor effects of formononetin on human nonsmall cell lung cancer (NSCLC) and its potential molecular mechanism. Methods: A549 cells were treated with
different concentrations of formononetin, then detected the cell proliferation, apoptosis and the expression of
HIPK2 respectively by MTT assay, flow cytometry analysis and RT-qPCR. Then the interaction between miR-
27a-3p and its target gene HIPK2 was verified through luciferase reporter assay. The expression of miR-27a-
3p, HIPK2, and p53 was detected after being treated with different formononetin concentrations by RT-qPCR
and western blot. Results: The results showed that formononetin significantly inhibited the proliferation and
induced the apoptosis of A549 cells in a time- and dose-dependent manner. miR-27a-3p targeted HIPK2
3’UTR and inhibited the expression of HIPK2. Also, formononetin-treated A549 cells were remarked with a
significant decline in the expression of miR-27a-3p, accompanied with growth of HIPK2, and subsequently a
reduction of p53. Conclusions: The study indicates that miR-27a-3p might pose regulated effects on the
HIPK2/p53 pathway, resulting in formononetin’s anti-carcinogenic effects on NSCLC in vitro.
KW - Non-small cell lung cancer (NSCLC); formononetin; miRNA; anti-cancer; p53 pathway
DO - 10.32604/Oncologie.2021.015828